Advertisement

Appropriateness of antithrombotic prophylaxis in the oldest old with non-valvular atrial fibrillation: ARAPACIS and REPOSI

Published:September 05, 2015DOI:https://doi.org/10.1016/j.ejim.2015.08.013
      In the frame of the Atrial Fibrillation Registry for Ankle–Brachial Index Prevalence Assessment-Collaborative Italian Study (ARAPACIS) involving 93 Internal Medicine wards, Pignatelli et al. [
      • Pignatelli P.
      • Pastori D.
      • Perticone F.
      • Corazza G.R.
      • Violi F.
      Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the ARAPACIS Study.
      ] conducted a questionnaire survey that, in addition to other questions, asked on the drugs of choice for prophylaxis of cardioembolism in patients with non-valvular atrial fibrillation (AF). Aspirin was chosen by 9% of the respondents, whereas oral anticoagulants were chosen by as many as 91% of the responders, 55% preferring vitamin K antagonists (VKAs) and 36% the non-vitamin K oral anticoagulants (NOACs) (of which dabigatran, rivaroxaban and apixaban are licensed in Italy).

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to European Journal of Internal Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Pignatelli P.
        • Pastori D.
        • Perticone F.
        • Corazza G.R.
        • Violi F.
        Lights and shadows in the management of old and new oral anticoagulants in the real world of atrial fibrillation by Italian internists. A survey from the ARAPACIS Study.
        Eur J Intern Med. 2015; https://doi.org/10.1016/j.ejim.2015.06.007
        • Mannucci P.M.
        • Nobili A.
        Multimorbidity and polypharmacy in the elderly: lessons from REPOSI.
        Intern Emerg Med. 2014; 9: 723-734
        • Marcucci M.
        • Iorio A.
        • Nobili A.
        • Tettamanti M.
        • Pasina L.
        • Marengoni A.
        • et al.
        Factors affecting adherence to guidelines for antithrombotic therapy in elderly patients with atrial fibrillation admitted to internal medicine wards.
        Eur J Intern Med. 2010; 21: 516-523
        • Ferro D.
        • Loffredo L.
        • Polimeni L.
        • Violi F.
        Underuse of oral anticoagulants in patients with nonvalvular atrial fibrillation in Italy.
        Intern Emerg Med. 2007; 2: 24-28
        • Marcucci M.
        • Nobili A.
        • Tettamanti M.
        • Iorio A.
        • Pasina L.
        • Djade C.D.
        • et al.
        Joint use of cardio-embolic and bleeding risk scores in elderly patients with atrial fibrillation.
        Eur J Intern Med. 2013; 24: 800-806
        • Mannucci P.M.
        Thromboprophylaxis in the oldest old with atrial fibrillation: between Scylla and Charybdis.
        Eur J Intern Med. 2013; 24: 285-287
        • van Walraven C.
        • Hart R.G.
        • Connolly S.
        • Austin P.C.
        • Mant J.
        • Hobbs F.D.
        • et al.
        Effect of age on stroke prevention therapy in patients with atrial fibrillation: the atrial fibrillation investigators.
        Stroke. 2009; 40: 1410-1416